NSCLC with 16 EGFR mutations, 2 ALK fusions, 1 ROS1 fusion, 1 ERBB2 mutation, and 3 wild-type after first-line standard or TKIs treatment failure. This evidence concerns the gene ALK and non-small cell lung carcinoma.